FDA To Consider Patient Input For Benefit-Risk Decisions For IDEs
This article was originally published in The Gray Sheet
The agency will take into account patient preferences when making benefit-risk determinations for investigational device exemptions, according to a June 18 draft guidance.
You may also be interested in...
FDA draft guidance lays out how to collect patient preference data and how to present the preferences on device labels. The guidance supports a growing emphasis by FDA to formally incorporate patient input into regulatory decision-making.
In an interview with “The Gray Sheet,” CDRH’s Acting Clinical Trials Director Owen Faris discusses the device center’s new pre-market clinical trials program aimed at speeding up approval times for investigational device exemptions and increasing the number of IDE trials in the U.S.
Congress has settled on final language for the FDA Safety and Innovation Act. After Senate approval, the bill will go to the White House for President Obama’s signature.